Navigation Links
Oramed Submits New IND Application for Oral Insulin Trial in the US

JERUSALEM, April 11, 2013 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (, a developer of oral drug delivery systems, announced today that it has submitted a new Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for a sub-study on its oral insulin candidate, ORMD-0801. This filing is in response to FDA feedback from Oramed's initial IND filing on December 31, 2012, wherein the FDA requested Oramed to perform a sub-study in a controlled in-patient setting for up to a one-week period prior to beginning the larger multi-centered Phase 2 trial.

"This new IND filing comes after ongoing productive communications with the FDA," stated Nadav Kidron , CEO of Oramed. "We look forward to receiving clearance on this IND and beginning our trials in the US."

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed's technology is based on over 30 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently approaching Phase 2 clinical trials under U.S. IND, and with its oral exenatide capsule (ORMD-0901; a GLP-1 analog), currently approaching Phase 2a trials. The company's corporate and R&D headquarters are based in Jerusalem.

The company's fact sheet can be viewed here.

For more information, the content of which is not part of this press release, please visit

Forward-looking statements: This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss receiving FDA clearance on this IND and our products approaching Phase 2 trials. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and final that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange Commission.

Company Contact:

Oramed Pharmaceuticals
Aviva Sherman
Cell: +972-54-792-4438
Office: +972-2-566-0001       

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Oramed Pharmaceuticals to Present at the 11th National Life Science & Technology Week ILSI-BIOMED Conference; Tel Aviv, Israel, 2012
2. Oramed Pharmaceuticals Granted Core Technology Patent in New Zealand
3. Oramed Pharmaceuticals to Present at the 12th Annual Diabetes Technology Society Meeting in Bethesda, MD, Nov 8-10, 2012
4. Oramed Pharmaceuticals Completes $5.6 Million Funding to Advance Clinical Trials
5. Oramed Pharmaceuticals Inc. to Webcast, Live, at on February 7th
6. Shares of Oramed Pharmaceuticals Are Approved for Listing on the Nasdaq Capital Market
7. Oramed Pharmaceuticals to Present at the 4th Annual Drug Delivery & Formulation Summit in Berlin
8. Oramed Pharmaceuticals Granted Japanese Patent for its Core Technology in Oral Delivery of Proteins
9. Zogenix Submits New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Zohydro™ for Treatment of Chronic Pain
10. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
11. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes
Post Your Comments:
(Date:11/25/2015)... 2015  The total global healthcare industry is expected to ... Latin America has the highest projected growth ... Japan ), is second with growth projected at ... increased healthcare expenditure. In 2013-2014, total government funded healthcare was ... 2008-2009 to 41.2% in 2013-2014. In real terms, out of ...
(Date:11/25/2015)...  The American Academy of Pediatrics (AAP), American ... March of Dimes cheered today,s signature into law ... of 2015 (S.799), which takes much-needed strides ... to drugs, such as opioids, and to improve ... organizations have worked together leading advocacy efforts for ...
(Date:11/25/2015)... , Nov. 25, 2015 AAIPharma ... planned investment of at least $15.8  Million to ... Wilmington, NC . The expansion will ... to meet the growing demands of the pharmaceutical ... site expansion will provide up to 40,000 ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... 2015 , ... The holiday season is jam-packed with family ... of attendees is of the utmost importance. Whether you are cooking at home ... recipes a try this holiday season. , Turkey Croquettes ,     Ingredients: ...
(Date:11/25/2015)... ... November 26, 2015 , ... Ministers, senior government and ... Pan African Centres of Excellence, and public R&D institutions, civil societies and other ... of the 5th African Network for Drugs and Diagnostics Innovation, ANDI, Stakeholders Meeting. ...
(Date:11/25/2015)... ... , ... Dental professionals who would like to become more proficient on their ... Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE course. Courses will be held on December ... of Advanced Implant Mentoring (AIM), Dr. Iacobelli and Dr. D’Orazio are proud to announce ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for the ... of the benefits of Botox® in the treatment of moderate facial wrinkling, few have ... pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism (the ...
(Date:11/25/2015)... PITTSBURGH, PA (PRWEB) , ... November 25, 2015 , ... ... rain,” said an inventor, from Bronx, N.Y. “I thought there had to be a ... She invented the PROTECTOR. , The PROTECTOR enables disabled individuals to safely travel during ...
Breaking Medicine News(10 mins):